Marché mondial des anti-inflammatoires non stéroïdiens topiques – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché des anti-inflammatoires non stéroïdiens topiques

Les anti-inflammatoires non stéroïdiens sont couramment utilisés pour traiter la douleur associée à diverses maladies, notamment les affections arthritiques, mais leur efficacité est parfois limitée par des événements indésirables (EI) dose-dépendants tels que des troubles gastro-intestinaux, des événements cardiovasculaires et une toxicité rénale. L'utilisation de formulations topiques, qui ont la capacité de fournir des doses analgésiques localement, au site de l'inflammation, tout en limitant les concentrations systémiques, pourrait réduire le risque de tels effets secondaires. La solution topique de diclofénac sodique à 1,5 pour cent (comprenant du diméthylsulfoxyde comme activateur de pénétration), le gel de diclofénac sodique à 1 pour cent et un patch de diclofénac hydroxyéthylpyrrolidine à 1,3 pour cent sont les seuls traitements topiques actuellement approuvés aux États-Unis.                                

Selon Data Bridge Market Research, le marché des anti-inflammatoires non stéroïdiens topiques, qui s'élevait à 2 648,65 millions USD en 2022, devrait atteindre 3 973,29 millions USD d'ici 2030 et devrait connaître un TCAC de 5,20 % au cours de la période de prévision. Les « génériques » dominent le segment des types de médicaments du marché des anti-inflammatoires non stéroïdiens topiques en raison de la demande croissante de versions génériques d'anti-inflammatoires non stéroïdiens topiques pour le traitement de diverses infections virales. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également des analyses approfondies d'experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

Nonsteroidal anti-inflammatory drugs (NSAIDs) are creams, gels, rubs, solutions, or sprays that include a nonsteroidal anti-inflammatory agent and are designed to be administered directly to the skin overlaying a painful joint or bone area. They're used to treat arthritic symptoms including inflammation, edema, and stiffness and decrease pain. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) can also be used to treat actinic keratosis (a precancerous patch of thick, scaly or crusted skin).            

Topical Non-Steroidal Anti-Inflammatory Drugs Market Dynamics

Drivers

• Aging population and increasing prevalence of arthritis

As the global population continues to age, the incidence of musculoskeletal conditions like osteoarthritis and rheumatoid arthritis is on the rise. Topical NSAIDs are often prescribed for pain relief and inflammation management, making them a preferred choice for many elderly patients. This demographic shift drives the demand for topical NSAIDs.

• Rising Sports-Related Injuries

The growing interest in sports and physical activities has led to an increased number of sports-related injuries. Topical NSAIDs are often recommended for the treatment of localized pain and inflammation caused by injuries. This trend is boosting the demand for topical NSAIDs in the sports medicine and physical therapy sectors.

• Growing investment for healthcare facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

• OTC availability and convenience

Many topical NSAIDs are available over-the-counter (OTC) without the need for a prescription. This easy accessibility appeals to consumers looking for quick pain relief solutions. Moreover, the convenience of topical applications, such as gels, creams, and patches, makes them a popular choice for self-administration. 

Opportunities

• Advanced drug delivery systems

Innovations in drug delivery systems, such as transdermal patches and nanoemulsions, offer an opportunity to enhance the effectiveness and convenience of topical NSAIDs. These technologies can improve drug penetration and reduce side effects, thereby increasing patient compliance and satisfaction. 

• Increasing consumer awareness

Educating consumers about the benefits of topical NSAIDs, including their safety profile compared to oral NSAIDs, can lead to greater acceptance and demand. Public health campaigns and targeted marketing efforts can help raise awareness and drive market growth. 

Restraints

• Competition from other pain management therapies

The topical NSAIDs market faces competition from other pain management options, including oral NSAIDs, opioids, physical therapy, and alternative therapies. The availability of a wide range of treatment options can limit the market's growth potential. 

• Stringent regulatory requirements

The regulatory environment for pharmaceuticals can be stringent, and gaining approval for new topical NSAIDs or expanding indications may be a time-consuming and costly process. Regulatory hurdles and delays can slow down market entry and product development. 

Challenges

• Safety concerns

While topical NSAIDs are generally considered safer than their oral counterparts in terms of systemic side effects, there are still safety concerns, particularly related to skin irritation and allergies. Adverse events, including skin reactions, can limit patient compliance and pose a restraint on the broader adoption of these drugs. 

• Generic competition

As patents for branded topical NSAIDs expire, generic versions of these drugs become available. This can lead to price erosion and reduced profit margins for manufacturers. Generic competition can limit revenue growth and market share for branded products. 

This topical non-steroidal anti-inflammatory drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the topical non-steroidal anti-inflammatory drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2022, Haleon launched Advil Plus Acetaminophen combining ibuprofen and acetaminophen, to fight pain in two ways. This is a product brought to market by Haleon since launching as an independent company focused entirely on consumer healthcare
• In May 2022, Dr. Reddy's laboratories launched the Ketorolac Tromethamine tablets USP, 10 mg, in the United States market. Ketorolac Tromethamine tablets, 10 mg, is a non-steroidal anti-inflammatory drug indicated for the short-term management of moderately severe acute pain. Source: https://www.mordorintelligence.com/industry-reports/non-steroidal-anti-inflammatory-drugs-market 

Global Topical Non-Steroidal Anti-Inflammatory Drugs Market Scope

The topical non-steroidal anti-inflammatory drugs market is segmented on the basis of indication, dosage form, drug type, age group, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Anti-inflammatory
• Analgesic
• Swelling
• Stiffness
• Skin Infections

Drug Type

• Branded
• Generics

Dosage Form

• Creams
• Gel
• Ointment
• Spray
• Rubs
• Solution
• Others

Age Group

• Pediatric
• Adult
• Geriatric

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Topical Non-Steroidal Anti-Inflammatory Drugs Market Regional Analysis/Insights

The topical non-steroidal anti-inflammatory drugs market is analyzed and market size insights and trends are provided by country, indication, dosage form, drug type, age group, end-users and distribution channel as referenced above.

The countries covered in the topical non-steroidal anti-inflammatory drugs market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

North America is expected to dominate the topical non-steroidal anti-inflammatory drugs market due to the growing number of research and development activities and presence of major key players in this region. Additionally the rising healthcare expenditure will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to surging government awareness programs and the increasing geriatric population in this region. Also, the development of healthcare infrastructure and the increasing number of generic drugs will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The topical non-steroidal anti-inflammatory drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for topical non-steroidal anti-inflammatory drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the topical non-steroidal anti-inflammatory drugs market. The data is available for historic period 2010-2020.

Competitive Landscape and Topical Non-Steroidal Anti-Inflammatory Drugs Market Share Analysis

The topical non-steroidal anti-inflammatory drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to topical non-steroidal anti-inflammatory drugs market.

Some of the major players operating in the topical non-steroidal anti-inflammatory drugs market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France), Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• Boehringer Ingelheim International GmbH. (Germany)
• Apotex Inc. (Canada)
• AstraZeneca (U.K.)
• Horizon Therapeutics PLC (Irlande)
• Johnson & Johnson (États-Unis)
• Bayer AG (Allemagne)
• Perrigo Company plc (Irlande)
• Tolmar Pharmaceuticals, Inc. (États-Unis)
• Reckitt Benckiser Group PLC (Royaume-Uni)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Assertio Therapeutics, Inc. (États-Unis)
• DAIICHI SANKYO COMPANY, LIMITED (Japon) 

SKU-53965